Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Non-Current Deffered Revenue (2018 - 2025)

10x Genomics' Non-Current Deffered Revenue history spans 6 years, with the latest figure at $10.5 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 16.08% year-over-year to $10.5 million; the TTM value through Dec 2025 reached $10.5 million, down 16.08%, while the annual FY2025 figure was $10.5 million, 16.08% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $10.5 million at 10x Genomics, down from $10.9 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $12.6 million in Q1 2025 and bottomed at $3.2 million in Q4 2022.
  • The 4-year median for Non-Current Deffered Revenue is $11.1 million (2025), against an average of $10.3 million.
  • The largest annual shift saw Non-Current Deffered Revenue skyrocketed 178.48% in 2023 before it dropped 16.08% in 2025.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $3.2 million in 2022, then surged by 178.48% to $8.8 million in 2023, then soared by 41.97% to $12.5 million in 2024, then decreased by 16.08% to $10.5 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Non-Current Deffered Revenue are $10.5 million (Q4 2025), $10.9 million (Q3 2025), and $11.3 million (Q2 2025).